Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies – State of the Art

References

• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. doi:10.1038/ni1102-99112407406
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–148. doi:10.1016/j.immuni.2004.07.01715308095
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosupressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:247–263. doi:10.1038/nrc1586
   Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527–5536. doi:10.1158/0008-5472.CAN-05-412816740684
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-011229684
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–217. doi:10.1016/j.ccr.2005.02.01315766659
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.02520303878
   PubMed Web of Science ®Google Scholar
• Aksoy E, Karakurt Z, Gungor S, et al. Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes. Int J Chron Obstruct Pulmon Dis. 2018;13:2721–2730. doi:10.2147/COPD.S17035330233162
   PubMed Web of Science ®Google Scholar
• Espinosa E, Feliu J, Zamora P, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 1995;12(1–2):67–76. doi:10.1016/0169-5002(95)00407-R7600032
   PubMed Web of Science ®Google Scholar
• Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006;53(1):97–101. doi:10.1016/j.lungcan.2006.03.01216698114
   PubMed Web of Science ®Google Scholar
• Heys SD, Walker LG, Deehan DJ, Eremin OE. Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb. 1998;43(3):163–168.9654876
   PubMedGoogle Scholar
• Lai CC, You JF, Yeh CY, et al. Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Colorectal Dis. 2011;26(4):473–481. doi:10.1007/s00384-010-1113-421190025
   PubMed Web of Science ®Google Scholar
• Dutta S, Crumley ABC, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg. 2012;204(3):294–299. doi:10.1016/j.amjsurg.2011.10.01522444831
   PubMed Web of Science ®Google Scholar
• Jiang X, Hiki N, Nunobe S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012;107(2):275–279. doi:10.1038/bjc.2012.26222713657
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103(9):1856–1864. doi:10.1002/cncr.2097615779015
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012;107(6):988–993. doi:10.1038/bjc.2012.35422878374
   PubMed Web of Science ®Google Scholar
• Crumley ABC, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94(11):1568–1571. doi:10.1038/sj.bjc.660315016685271
   PubMed Web of Science ®Google Scholar
• Crumley ABC, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94(5):637–641. doi:10.1038/sj.bjc.660299816479253
   PubMed Web of Science ®Google Scholar
• Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA. Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J Parenter Enteral Nutr. 2003;27(1):10–15. doi:10.1177/01486071030270011012549592
   PubMed Web of Science ®Google Scholar
• Al Murri AM, Bartlett JMS, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94(2):227–230. doi:10.1038/sj.bjc.660292216404432
   PubMed Web of Science ®Google Scholar
• Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217–224. doi:10.1245/s10434-011-1814-021638095
   PubMed Web of Science ®Google Scholar
• Parker D, Bradley C, Bogle SM, et al. Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. BJOG. 1994;101(10):888–893. doi:10.1111/j.1471-0528.1994.tb13550.x
   Web of Science ®Google Scholar
• Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710–714. doi:10.1158/1078-0432.CCR-07-104418245530
   PubMed Web of Science ®Google Scholar
• Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15–23. doi:10.1007/s00262-008-0516-318414853
   PubMed Web of Science ®Google Scholar
• Polterauer S, Grimm C, Seebacher V, et al. The inflammation-based Glasgow prognostic score predicts survival in patients with cervical cancer. Int J Gynecol Cancer. 2010;20(6):1052–1057. doi:10.1111/IGC.0b013e3181e64bb120683416
   PubMed Web of Science ®Google Scholar
• Lee YY, Choi CH, Kim HJ, et al. Pretreatment neutrophil: lymphocyteratio as a prognostic factor in cervical carcinoma. Anticancer Res. 2012;32(4):1555–1561.22493401
   PubMed Web of Science ®Google Scholar
• La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G. The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012;19(9):2917–2923. doi:10.1245/s10434-012-2348-922488099
   PubMed Web of Science ®Google Scholar
• Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005;95(7):961–962. doi:10.1111/j.1464-410X.2005.05447.x15839913
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma specific mortality: a European study of 313 patients. Cancer. 2007;110(6):1241–1247. doi:10.1002/cncr.2289617639589
   PubMed Web of Science ®Google Scholar
• Hilmy M, Bartlett JMS, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer. 2005;92(4):625–627. doi:10.1038/sj.bjc.660240615726119
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med. 2019;39(4):345–357. doi:10.3343/alm.2019.39.4.34530809980
   PubMed Web of Science ®Google Scholar
• Jin Z, Cai G, Zhang P, et al. The value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as complementary diagnostic tools in the diagnosis of rheumatoid arthritis: a multicenter retrospective study. J Clin Lab Anal. 2021;35(1):e23569. doi:10.1002/jcla.2356932951253
   PubMed Web of Science ®Google Scholar
• Chandrashekara S, Lingaraju DC, Renuka P, Anupama KR. Potential of neutrophil to lymphocyte ratio in predicting sustained remission in rheumatoid arthritis compared to other immune activation markers. Indian J Med Res. 2020;152(3):234–243. doi:10.4103/ijmr.IJMR_1676_1833107483
   PubMed Web of Science ®Google Scholar
• Gökmen F, Akbal A, Reşorlu H, et al. Neutrophil-lymphocyte ratio connected to treatment options and inflammation markers of ankylosing spondylitis. J Clin Lab Anal. 2015;29(4):294–298. doi:10.1002/jcla.2176824849656
   PubMed Web of Science ®Google Scholar
• Xu S, Ma Y, Wu M, et al. Neutrophil lymphocyte ratio in patients with ankylosing spondylitis: a systematic review and meta-analysis. Mod Rheumatol. 2020;30(1):141–148. doi:10.1080/14397595.2018.156416530605008
   PubMed Web of Science ®Google Scholar
• Feng JR, Qiu X, Wang F, et al. Diagnostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Crohn’s disease. Gastroenterol Res Pract. 2017;2017:3526460. doi:10.1155/2017/352646028798770
   PubMed Web of Science ®Google Scholar
• Mertoglu C, Gunay M. Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab Syndr. 2017;Suppl 1:S127–S131. doi:10.1016/j.dsx.2016.12.021
   Web of Science ®Google Scholar
• Bilge M, Yesilova A, Adas M, Helvaci A. Neutrophil- and platelet- to lymphocyte ratio in patients with Euthyroid Hashimoto’s thyroiditis. Exp Clin Endocrinol Diabetes. 2019;127(8):545–549. doi:10.1055/a-0723-344130267388
   PubMed Web of Science ®Google Scholar
• Tatum D, Taghavi S, Houghton A, Stover J, Toraih E, Duchesne J. Neutrophil-to-lymphocyte ratio and outcomes in Louisiana COVID-19 patients. Shock. 2020;54(5):652–658. doi:10.1097/SHK.000000000000158532554992
   PubMed Web of Science ®Google Scholar
• Howard R, Scheiner A, Kanetsky PA, Egan KM. Sociodemographic and lifestyle factors associated with the neutrophil-to-lymphocyte ratio. Ann Epidemiol. 2019;38:11–21 e6. doi:10.1016/j.annepidem.2019.07.01531481293
   PubMed Web of Science ®Google Scholar
• Nowak-Markwitz E, Spaczyński M. Rak jajnik – nowe spojrzenie na pochodzenie i histogenezę [Ovarian cancer – modern approach to its origin and histogenesis]. Ginekol Pol. 2012;83:454–457. Polish.22880466
   PubMed Web of Science ®Google Scholar
• Shih L, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–1518. doi:10.1016/S0002-9440(10)63708-X15111296
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumor – educated macrophages promote tumor progression and metastasis. Nat Rev Cancer. 2004;4:71–78. doi:10.1038/nrc125614708027
   PubMed Web of Science ®Google Scholar
• Hofmeister V, Vetter C, Schrama D, Bröcker EB, Becker JC. Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunol Immunother. 2006;55:481–494. doi:10.1007/s00262-005-0070-116220326
   PubMed Web of Science ®Google Scholar
• Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004;104:2224–2234. doi:10.1182/blood-2004-03-110915231578
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–555. doi:10.1016/S1471-4906(02)02302-512401408
   PubMed Web of Science ®Google Scholar
• Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2016;99(Pt B):180–185. doi:10.1016/j.addr.2015.11.00926621196
   PubMed Web of Science ®Google Scholar
• Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–266. doi:10.1016/j.cell.2006.01.00716439202
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–612. doi:10.1158/0008-5472.CAN-05-400516423985
   PubMed Web of Science ®Google Scholar
• Kim J, Bae JS. Tumor-associated macrophages and neutrophil in tumor microenvironment. Mediators Inflamm. 2016;2016:6058147. doi:10.1155/2016/605814726966341
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66(7):3859–3868. doi:10.1158/0008-5472.CAN-05-394816585214
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603–1616.20840865
   PubMed Web of Science ®Google Scholar
• de Sá Junior PL, Câmara DAD, Porcacchia AS, et al. The roles of ROS in cancer heterogeneity and therapy. Oxid Med Cell Longev. 2017;2017:1–12. doi:10.1155/2017/2467940
   Web of Science ®Google Scholar
• Galdiero MR, Bonavita E, Barajon I, et al. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218(11):1402–1410. doi:10.1016/j.imbio.2013.06.00323891329
   PubMed Web of Science ®Google Scholar
• Mantovani A. Macrophages, neutrophils, and cancer: a double edged sword. New J Sci. 2014;2014:1–14. doi:10.1155/2014/271940
   Google Scholar
• Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012;33(5):949–955. doi:10.1093/carcin/bgs12322425643
   PubMed Web of Science ®Google Scholar
• Sagiv JY, Michaeli J, Assi S, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10:562–573. doi:10.1016/j.celrep.2014.12.03925620698
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454. doi:10.1056/NEJM1999021134006079971870
   PubMed Web of Science ®Google Scholar
• Kim ES, Kim SY, Koh M, et al. C-reactive protein binds to integrin α2 and Fcγ receptor I, leading to breast cell adhesion and breast cancer progression. Oncogene. 2018;37(1):28–38. doi:10.1038/onc.2017.29828846105
   PubMed Web of Science ®Google Scholar
• Kim ES, Cha Y, Ham M, et al. Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPbeta and potentiates breast cancer progression. Oncogene. 2014;33(27):3583–3593. doi:10.1038/onc.2013.31923955082
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13(3):R55. doi:10.1186/bcr289121639875
   PubMed Web of Science ®Google Scholar
• Mantzorou M, Koutelidakis A, Theocharis S, Giaginis C. Clinical value of nutritional status in cancer: what is its impact and how it affects disease progression and prognosis? Nutr Cancer. 2017;69(8):1151–1176. doi:10.1080/01635581.2017.136794729083236
   PubMed Web of Science ®Google Scholar
• Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69. doi:10.1186/1475-2891-9-6921176210
   PubMed Web of Science ®Google Scholar
• Rahman MM, Ahsan MA, Monalisa NN, Rahman K. Influence of socioeconomic status and BMI on the quality of life after mastectomy in Bangladeshi breast cancer patients in a public hospital. Jpn J Clin Oncol. 2014;44(12):1150–1157. doi:10.1093/jjco/hyu14425425727
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, McMillan DC. Role of systemic infammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–163. doi:10.2217/fon.09.13620021215
   PubMed Web of Science ®Google Scholar
• Viganò A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160(6):861–868.10737287
   PubMed Web of Science ®Google Scholar
• Sica A, Erreni M, Allavena P, Porta C. Macrophage polarization in pathology. Cell Mol Life Sci. 2015;72(21):4111–4126. doi:10.1007/s00018-015-1995-y26210152
   PubMed Web of Science ®Google Scholar
• Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13(5):1221–1230. doi:10.1200/JCO.1995.13.5.12217738625
   PubMed Web of Science ®Google Scholar
• Teramukai S, Kinato T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan multinational trial organization LC00-03. Eur J Cancer. 2009;45:1950–1958. doi:10.1016/j.ejca.2009.01.02319231158
   PubMed Web of Science ®Google Scholar
• Lu CC, Chang KW, Chou FC, et al. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol. 2007;43:282–288. doi:10.1016/j.oraloncology.2006.03.010
   Web of Science ®Google Scholar
• Pedersen LM, Milman N. Diagnostic significance of platelet count and other blood analyses in patients with lung cancer. Oncol Rep. 2003;10:213–216.12469171
   PubMed Web of Science ®Google Scholar
• Unal D, Eroglu C, Kurtul N, et al. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis. Asian Pac J Cancer Prev. 2013;14:5237–5242. doi:10.7314/APJCP.2013.14.9.523724175807
   PubMed Web of Science ®Google Scholar
• Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;36(3):617–622. doi:10.1007/s00268-011-1411-122223293
   PubMed Web of Science ®Google Scholar
• Williams KA, Labidi-Galy I, Terry KL, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014;132(3):542–550. doi:10.1016/j.ygyno.2014.01.02624462730
   PubMed Web of Science ®Google Scholar
• Zhou Q, Hong L, Zuo MZ, He Z. Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4910 patients. Oncotarget. 2017;8(40):68938–68949. doi:10.18632/oncotarget.2019628978169
   PubMedGoogle Scholar
• Gu L, Li H, Chen L, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7(22):31926–31942. doi:10.18632/oncotarget.787626942464
   PubMedGoogle Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.626128974892
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-044225271081
   PubMed Web of Science ®Google Scholar
• Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond). 2009;9(1):30–33. doi:10.7861/clinmedicine.9-1-3019271597
   PubMed Web of Science ®Google Scholar
• Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One. 2013;8(3):e59321. doi:10.1371/journal.pone.005932123555017
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803–810. doi:10.1245/s10434-014-4048-025190127
   PubMed Web of Science ®Google Scholar
• Liu X, Sun X, Liu J, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 2015;8(4):339–345. doi:10.1016/j.tranon.2015.06.00626310380
   PubMed Web of Science ®Google Scholar
• Xu XL, Yu HQ, Hu W, Song Q, Mao WM. A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One. 2015;10(9):e0138657. doi:10.1371/journal.pone.013865726390126
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen S, Zheng C, et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer. 2017;17(1):285. doi:10.1186/s12885-017-3220-x28431566
   PubMed Web of Science ®Google Scholar
• Zhou L, Ma S, Balde AI, et al. A retrospective propensity score matched study of the preoperative C-reactive protein to albumin ratio and prognosis in patients with resectable non-metastatic breast cancer. Med Sci Monit. 2019;25:4342–4352. doi:10.12659/MSM.91368431182704
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Stankowski RV, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2- positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012;134(1):291–298. doi:10.1007/s10549-012-2039-z22476854
   PubMed Web of Science ®Google Scholar
• Forrest LM, McMillian DC, McArdle CS et al. Evaluation of cumulatrive prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89:1028–1030
   Google Scholar
• Dolan RD, Lim J, McSorley ST, et al. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7(1):16717.29196718
   PubMed Web of Science ®Google Scholar
• Staton CA, Brown NJ, Lewis CE. The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opin Biol Ther. 2003;3(7):1105–1120. doi:10.1517/14712598.3.7.110514519075
   PubMed Web of Science ®Google Scholar
• Martino MM, Briquez PS, Ranga A, et al. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci U S A. 2013;110(12):4563–4568. doi:10.1073/pnas.122160211023487783
   PubMed Web of Science ®Google Scholar
• Xu Q, Yan Y, Gu S, et al. A novel inflammation-based prognostic score: the fibrinogen/albumin ratio predicts prognoses of patients after curative resection for hepatocellular carcinoma. J Immunol Res. 2018;2018:4925498. doi:10.1155/2018/492549830027102
   PubMed Web of Science ®Google Scholar
• Perisanidis C, Psyrri A, Cohen EE, et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):960–970. doi:10.1016/j.ctrv.2015.10.00226604093
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22. doi:10.1038/nrc274820029421
   PubMed Web of Science ®Google Scholar
• Tan Z, Zhang M, Han Q, et al. A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the fibrinogen/albumin ratio. J Cancer. 2017;8(6):1025–1029. doi:10.7150/jca.1649128529615
   PubMed Web of Science ®Google Scholar
• Li X, An B, Zhao Q, et al. Combined fibrinogen and neutrophil–lymphocyte ratio as a predictive factor in resectable colorectal adenocarcinoma. Cancer Manag Res. 2018;10:6285–6294. doi:10.2147/CMAR.S16109430568490
   PubMed Web of Science ®Google Scholar
• Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64.31456179
   PubMed Web of Science ®Google Scholar
• Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2. doi:10.1186/s13058-016-0794-128057046
   PubMed Web of Science ®Google Scholar
• Koh YW, Lee HJ, Ahn JH, Lee JW, Gong G. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumor Biol. 2014;35(10):9823–9830. doi:10.1007/s13277-014-2282-5
   PubMedGoogle Scholar
• Corbeau I, Jacot W, Guiu S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review. Cancers (Basel). 2020;12(4):958. doi:10.3390/cancers12040958
   PubMed Web of Science ®Google Scholar
• Cullinane C, Creavin B, O’Leary DP, et al. Can the neutrophil to lymphocyte ratio predict complete pathologic response to neoadjuvant breast cancer treatment? A systematic review and meta-analysis. Clin Breast Cancer. 2020;20(6):e675–e681. doi:10.1016/j.clbc.2020.05.00832653471
   PubMed Web of Science ®Google Scholar
• Iwase T, Sangai T, Sakakibara M, et al. An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer. Mol Clin Oncol. 2017;6(2):266–270. doi:10.3892/mco.2016.110128357108
   PubMed Web of Science ®Google Scholar
• Miyagawa Y, Araki K, Bun A, et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin Breast Cancer. 2018;18(5):400–409. doi:10.1016/j.clbc.2018.03.00229605174
   PubMed Web of Science ®Google Scholar
• Takuwa H, Tsuji W, Yamamoto Y, et al. Low neutrophil-lymphocyte ratio correlates with extended survival in patients with metastatic breast cancer who achieved clinically complete response following multidisciplinary therapy: a retrospective study. Oncol Lett. 2018;15(5):6681–6687. doi:10.3892/ol.2018.814529725410
   PubMed Web of Science ®Google Scholar
• Cho U, Park HS, Im SY, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One. 2018;13(7):e0200936. doi:10.1371/journal.pone.020093630048474
   PubMed Web of Science ®Google Scholar
• Araki K, Ito Y, Fukada I, et al. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer. 2018;18(1):982. doi:10.1186/s12885-018-4888-230326862
   PubMed Web of Science ®Google Scholar
• Vernieri C, Mennitto A, Prisciandaro M, et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. Sci Rep. 2018;8(1):1–10. doi:10.1038/s41598-018-27075-z29311619
   PubMed Web of Science ®Google Scholar
• Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol. 2020;18(1):197. doi:10.1186/s12957-020-01974-w32767977
   PubMed Web of Science ®Google Scholar
• Chen L, Kong X, Wang Z, et al. Pretreatment systemic inflammation response index in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. Cancer Manag Res. 2020;12:1543–1567. doi:10.2147/CMAR.S23551932184659
   PubMed Web of Science ®Google Scholar
• Zhao X, Qu J, Sun Y, et al. Prognostic significance of tumor- associated macrophages in breast cancer: a meta- analysis of the literature. Oncotarget. 2017;8(18):30576–30586. doi:10.18632/oncotarget.1573628427165
   PubMedGoogle Scholar
• Banas T, Juszczyk G, Pitynski K, et al. Incidence and mortality rates in breast, corpus uteri, and ovarian cancers in Poland (1980–2013): an analysis of population-based data in relation to socioeconomic changes. Onco Targets Ther. 2016;9:5521–5530. doi:10.2147/OTT.S11218727660470
   PubMed Web of Science ®Google Scholar
• Cakmak B, Gulucu S, Aliyev N, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios in endometrial hyperplasia. Obstet Gynecol Sci. 2015;58(2):157–161. doi:10.5468/ogs.2015.58.2.15725798430
   PubMedGoogle Scholar
• Ural ÜM, Şehitoğlu İ, Tekin YB, Şahin FK. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res. 2015;41(3):445–448. doi:10.1111/jog.1253625363740
   PubMed Web of Science ®Google Scholar
• Selen S, Kilic F, Kimyon Comert G, et al. Can preoperative inflammatory markers differentiate endometrial cancer from complex atypical hyperplasia/endometrial intraepithelial neoplasia? J Obstet Gynaecol Res. 2020;46(7):1148–1156. doi:10.1111/jog.1431432464701
   PubMed Web of Science ®Google Scholar
• Acmaz G, Aksoy H, Unal D, et al. Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding? Asian Pac J Cancer Prev. 2014;15(4):1689–1692. doi:10.7314/APJCP.2014.15.4.168924641391
   PubMedGoogle Scholar
• Pergialiotis V, Oikonomou M, Damaskou V, et al. Platelet to lymphocyte and neutrophil to lymphocyte ratio as predictive indices of endometrial carcinoma: findings from a retrospective series of patients and meta-analysis. J Gynecol Obstet Hum Reprod. 2018;47(10):511–516. doi:10.1016/j.jogoh.2018.08.01630153505
   PubMed Web of Science ®Google Scholar
• NSSN guidelines [homepage on the internet] Clinical Practice Guidelines in Oncology; 2021. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 320, 2021.
   Google Scholar
• Haruma T, Nakamura K, Nishida T. Pre-treatment neutrophil to lymphocyte ratio is a predictor of prognosis in endometrial cancer. Anticancer Res. 2015;35(1):337–343.25550569
   PubMed Web of Science ®Google Scholar
• Kadan Y, Calvino AS, Katz A, Katz S, Moore RG. Predictors for lymph nodes involvement in low risk endometrial cancer. J Obstet Gynaecol. 2017;37(4):514–518. doi:10.1080/01443615.2017.128189528339318
   PubMedGoogle Scholar
• Cong R, Kong F, Ma J, Li Q, Wu Q, Ma X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer. BMC Cancer. 2020;20(1):464. doi:10.1186/s12885-020-06953-832448185
   PubMed Web of Science ®Google Scholar
• Eo WK, Kwon S, Koh SB. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial cancer. J Cancer. 2016;7(5):538–545. doi:10.7150/jca.1420627053952
   PubMed Web of Science ®Google Scholar
• Li J, Lin J, Luo Y, Kuang M, Liu Y. Multivariate analysis of prognostic biomarkers in surgically treated endometrial cancer. PLoS One. 2015;10(6):e0130640. doi:10.1371/journal.pone.013064026107255
   PubMed Web of Science ®Google Scholar
• Kübler K, Ayub TH, Weber SK, et al. Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol Oncol. 2014;135(2):176–183. doi:10.1016/j.ygyno.2014.08.02825173585
   PubMed Web of Science ®Google Scholar
• Kelly MG, Francisco AM, Cimic A, et al. Type 2 endometrial cancer is associated with a high density of tumor associated macrophages in the stromal compartment. Reprod Sci. 2015;22(8):948–953. doi:10.1177/193371911557091225701837
   PubMed Web of Science ®Google Scholar
• Dai D, Liu L, Huang H, et al. Nomograms to predict the density of tumor-infiltrating lymphocytes in patients with high-grade serous ovarian cancer. Front Oncol. 2021;11:590414. doi:10.3389/fonc.2021.59041433718143
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhao X, Lu J, et al. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Arch Gynecol Obstet. 2018;297(4):849–857. doi:10.1007/s00404-018-4678-829368160
   PubMed Web of Science ®Google Scholar
• Huang QT, Zhou L, Zeng WJ, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in ovarian cancer: a systematic review and meta-analysis of observational studies. Cell Physiol Biochem. 2017;41(6):2411–2418. doi:10.1159/00047591128467978
   PubMedGoogle Scholar
• Zhang H, Huo Q, Huang L, Cheng Y, Liu Y, Bao H. Neutrophil-to-lymphocyte ratio in ovarian cancer patients with low CA125 concentration. Biomed Res Int. 2019;2019:8107906.31341906
   PubMed Web of Science ®Google Scholar
• Wu YY, Qin YY, Qin JQ, Zhang X, Lin FQ. Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer. J Clin Lab Anal. 2019;33(4):e22833. doi:10.1002/jcla.2283330666724
   PubMed Web of Science ®Google Scholar
• Lu C, Zhou L, Ouyang J, Yang H. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis. Medicine (Baltimore). 2019;98(24):e1587. doi:10.1097/MD.0000000000015876
   Web of Science ®Google Scholar
• Zhang M, He Y, Sun X, et al. A high M1/M2 ratio of tumor associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:19. doi:10.1186/1757-2215-7-1924507759
   PubMed Web of Science ®Google Scholar
• Yin M, Shen J, Yu S, et al. Tumor-Associated Macrophages (TAMs): a critical activator in ovarian cancer metastasis. Onco Targets Ther. 2019;21(12):8687–8699. doi:10.2147/OTT.S216355
   Web of Science ®Google Scholar
• Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev. 2018;19(2):319–324. doi:10.22034/APJCP.2018.19.2.31929479954
   PubMedGoogle Scholar
• Tas M, Yavuz A, Ak M, Ozcelik B. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in discriminating precancerous pathologies from cervical cancer. J Oncol. 2019;2019:2476082. doi:10.1155/2019/247608231558903
   PubMed Web of Science ®Google Scholar
• Prabawa IPY, Bhargah A, Liwang F, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pac J Cancer Prev. 2019;20(3):863–868. doi:10.31557/APJCP.2019.20.3.86330912405
   PubMedGoogle Scholar
• Zhu M, Feng M, He F, et al. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical cancer. Clin Chim Acta. 2018;483:296–302. doi:10.1016/j.cca.2018.05.02529758203
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang H, Gao MJ, et al. Prognostic values of lymphocyte and eosinophil counts in resectable cervical squamous cell carcinoma. Future Oncol. 2019;15(30):3467–3481. doi:10.2217/fon-2018-087931580723
   PubMed Web of Science ®Google Scholar
• Trinh H, Dzul SP, Hyder J, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). Clin Chim Acta. 2020;510:711–716. doi:10.1016/j.cca.2020.09.00832919942
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu K, Ye B, Liang W, Ren Y. Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer. Cancer Med. 2018;7(1):105–113. doi:10.1002/cam4.127029193777
   PubMed Web of Science ®Google Scholar
• Ding H, Cai J, Mao M, et al. Tumor-associated macrophages induce lymphangiogenesis in cervical cancer via interaction with tumor cells. APMIS. 2014;122(11):1059–1069. doi:10.1111/apm.1225724698523
   PubMed Web of Science ®Google Scholar
• Chen X-J, Han L-F, Wu X-G, et al. Clinical significance of CD163+ and CD68+ tumor-associated macrophages in high-risk HPV-related cervical cancer. J Cancer. 2017;8(18):3868–3875. doi:10.7150/jca.2144429151975
   PubMed Web of Science ®Google Scholar
• Banas T, Pitynski K, Jach R, et al. Primary vulvo-vaginal cancers: trends in incidence and mortality in Poland (1999–2012). Gynecol Obstet Invest. 2015;80(4):240–245. doi:10.1159/00038177026065364
   PubMed Web of Science ®Google Scholar
• Ertas IE, Gungorduk K, Akman L, et al. Can preoperative neutrophil: lymphocyteand platelet: lymphocyteratios be used as predictive markers for lymph node metastasis in squamous cell carcinoma of the vulva? Eur J Obstet Gynecol Reprod Biol. 2013;171(1):138–142. doi:10.1016/j.ejogrb.2013.08.02323992992
   PubMed Web of Science ®Google Scholar
• Six L, Polterauer S, Grimm C, et al. C-reactive protein serum levels are closely associated with lymph node status, but not with prognosis in patients with vulvar cancer. Eur J Obstet Gynecol Reprod Biol. 2008;137(2):217–221. doi:10.1016/j.ejogrb.2007.02.02017459567
   PubMed Web of Science ®Google Scholar
• Kim HS, Choi HY, Lee M, et al. Systemic inflammatory response markers and CA-125 levels in ovarian clear cell carcinoma: a Two Center Cohort Study. Cancer Res Treat. 2016;48(1):250–258. doi:10.4143/crt.2014.32425761476
   PubMed Web of Science ®Google Scholar
• Fader AN, Java J, Krivak TC, et al. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. Gynecol Oncol. 2014;132:560–565. doi:10.1016/j.ygyno.2013.11.01624333362
   PubMed Web of Science ®Google Scholar
• Kim I-H, Lee JE, Yang JH, et al. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response. Asia Pac J Clin Oncol. 2018;14(3):239–246. doi:10.1111/ajco.1278429044941
   PubMed Web of Science ®Google Scholar
• Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P. Breast cancer statistics and markers. J Cancer Res Ther. 2014;10(3):506–11.25313729
   PubMed Web of Science ®Google Scholar
• Chernecky CC, Berger BJ. Laboratory Tests and Diagnostic Procedures. Elsevier Health Sciences; 2007:s. 269–270.
   Google Scholar
• Hewala TI, Abd El-Monaim NA, Anwar M, Ebied SA. The clinical significance of serum soluble Fas and p53 protein in breast cancer patients: comparison with serum CA 15-3. Pathol Oncol Res. 2012;18(4):841–848. doi:10.1007/s12253-012-9512-122422199
   PubMed Web of Science ®Google Scholar